AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for 14 kDa phosphohistidine phosphatase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NRX4

UPID:

PHP14_HUMAN

Alternative names:

Phosphohistidine phosphatase 1; Protein histidine phosphatase; Protein janus-A homolog

Alternative UPACC:

Q9NRX4; B1AMX0; B1AMX1; Q9H0Y3

Background:

The 14 kDa phosphohistidine phosphatase, also known as Phosphohistidine phosphatase 1, Protein histidine phosphatase, and Protein janus-A homolog, plays a crucial role in cellular processes through its phosphohistidine phosphatase activity. This enzyme is pivotal in the regulation of phosphorylation, a key post-translational modification affecting numerous cellular pathways.

Therapeutic significance:

Understanding the role of 14 kDa phosphohistidine phosphatase could open doors to potential therapeutic strategies. Its unique enzymatic activity suggests a significant, yet untapped, potential in drug discovery, particularly in diseases where phosphorylation plays a critical role.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.